Lilly Lifts 2026 Revenue Outlook to as Much as $92 Billion as Mounjaro and Zepbound Beat Estimates

Eli Lilly lifted its full-year revenue forecast to as much as $92 billion after strong Q3 sales of Mounjaro and Zepbound beat estimates, while trimming profit guidance on deal charges.